$ABBV
ABBV · Healthcare
- Market cap
- —
- Volume
- —
- P/E
- —
- Day range
- — – —
- 52w range
- — – —
- Analyst target
- —
AI Summary
Generating a unique summary for ABBV…
AI-generated for information only — not investment advice.
Share this ticker
$ABBV David Tepper and 0 other tracked billionaires hold it. $JNJ $NTRA $LLY https://billionairestrading.com/stocks/ABBV
Company summary
Immunology and oncology drugs.
Institutional ownership
Institutions hold —% · insiders —%
No institutional filings available for this ticker.
Hedge fund & billionaire activity
Insider transactions
No insider transactions reported.
Analyst ratings
Consensus score — (1 = strong buy, 5 = sell) · mean target —
No recent analyst actions.
Earnings
Next report: not scheduled
No earnings history available.
SEC filings
No filings indexed for this ticker.
Latest ABBV news
- AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Fri, 04 Sep 2026 18:50:01 +0000
- ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
Fri, 04 Sep 2026 14:48:00 +0000
- AbbVie’s Humira Cash Cow Is Shrinking—Can Its Dividend Keep Growing?
AbbVie's flagship drug is bleeding revenue quarter after quarter, yet the company just handed shareholders another raise. Find out whether the cash machine holding this payout together can survive the patent reckoning already underway.
Fri, 04 Sep 2026 13:59:10 +0000
- The Zacks Analyst Blog Highlights Amazon.com, AbbVie, Alibaba and Lulu's Fashion Lounge
Amazon's diversified growth and AI push, AbbVie's pipeline, Alibaba's cloud gains and Lulu's improving margins shape these analyst picks.
Fri, 04 Sep 2026 13:29:00 +0000
- Here Are 5 ETFs That Retirees Use to Skip Stock Picking Entirely
Owning two or three dividend ETFs feels like extra protection, but it can quietly leave retirees paying multiple expense ratios for a nearly identical stack of stocks. Here is how the five most popular options actually differ, and why the wrong combination costs more than most people realize.
Fri, 04 Sep 2026 12:00:36 +0000
- Trailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
Fri, 04 Sep 2026 12:00:00 +0000
- AbbVie (ABBV) Reports Positive Phase 3 Results For Etentamig In Multiple Myeloma
AbbVie (NYSE: ABBV) reported positive Phase 3 CERVINO trial results for etentamig, an investigational BCMA x CD3 bispecific T-cell engager in relapsed or refractory multiple myeloma. The study found etentamig outperformed standard therapies with strong efficacy and a manageable safety profile in a difficult-to-treat patient group. The data may support a future regulatory submission and potential market entry for etentamig in the BCMA-targeted therapies space. Consider reviewing other...
Fri, 04 Sep 2026 08:19:32 +0000
- AbbVie (ABBV)’s Blood Cancer Success Adds Weight to its Pipeline Story
AbbVie Inc. (NYSE:ABBV)’s experimental blood-cancer therapy etentamig delivered positive results in a late-stage trial for patients with relapsed or refractory multiple myeloma, meeting the trial’s main objectives. The drug produced an objective response rate of 74%, compared with 45.7% for standard treatments selected by investigators. More importantly, etentamig reduced the risk of disease progression or […]
Fri, 04 Sep 2026 01:24:34 +0000